Eli Lilly and MacroGenics have entered into an alliance to develop and commercialize teplizumab, a humanized anti-CD3 monoclonal antibody, and other potential next-generation anti-CD3 molecules for the treatment of autoimmune diseases.
Lilly will acquire the exclusive rights to teplizumab, which is being studied in the Phase II/III PROTÉGÉ trial for individuals with recent-onset Type 1 diabetes. MacroGenics will continue to oversee the PROTÉGÉ trial.
If teplizumab is commercialized successfully, MacroGenics may receive up to $250 million in potential sales milestones. MacroGenics also would have the option to co-promote teplizumab for certain indications in the U.S., MacroGenics said.